Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 63Ovarian Neoplasms 8Neoplasm Metastasis 8Endometrial Neoplasms 6Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms by Site 3Colorectal Neoplasms 3Breast Diseases 3Small Cell Lung Carcinoma 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Head and Neck Neoplasms 2Uterine Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Locoregional Recurrence 1

Interventions

Etoposide 30Carboplatin 29atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11Specimen Handling 9PM 01183 9Magnetic Resonance Spectroscopy 7pembrolizumab 6olaparib 5berzosertib 4anlotinib 4Radiotherapy 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Paclitaxel 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2cabozantinib 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Fulvestrant × 90 days × Clear all
NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Active not recruiting
103 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Pfizer

Phase 2 Active not recruiting
157 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡